425310login-checkCareDx Demonstrates Potential of AlloHeme and AlloCell for Allogeneic Cell Transplant and Therapy Monitoring at Transplantation & Cellular Therapy Meetings |
CareDx Announces that OTTR Patient Management Software Now Validated for SMART on FHIR
SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the presentation of new data during the Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR being held on April 23-26 in Salt Lake City, Utah, highlighting the capabilities of AlloHeme™ and AlloCell for allogeneic cell transplant and therapy monitoring.
Read the full press release on CareDx.com here.
425310login-checkCareDx Demonstrates Potential of AlloHeme and AlloCell for Allogeneic Cell Transplant and Therapy Monitoring at Transplantation & Cellular Therapy Meetings |